Passage Bio, Inc. (PASG)Healthcare | Biotechnology | Philadelphia, United States | NasdaqCM
4.52 USD
+0.19
(4.388%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.52 |
Hot Take ↕ | Aug. 22, 2026, 2:40 a.m. EDT
The immediate outlook remains heavily skewed toward caution due to a relentless five-year price collapse and deteriorating financials. While the recent dip to $4.44 offers a temporary relief from the 52-week high of $20, the underlying business is bleeding cash aggressively with negative free cash flow and a massive operating burn. The balance sheet is fragile, with a current ratio barely above 1.2 and no earnings to support operations. Although a merger agreement with Remix Therapeutics provides a potential catalyst for restructuring, the valuation metrics—negative forward P/E and a price-to-book ratio significantly above par given the losses—suggest the market has already priced in significant distress. Without a confirmed path to profitability or a substantial cash infusion beyond the merger terms, the risk of further downside outweighs the speculative upside. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.038869 |
| AutoTheta | 0.063680 |
| AutoETS | 0.066444 |
| AutoARIMA | 0.126197 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.41 |
| Ljung-Box p | 0.002 |
| Jarque-Bera p | 0.532 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 14,544,501 |
| Forward P/E | -0.44 |
| Beta | 1.43 |
| Website | https://www.passagebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3909986 |
| Address1 | One Commerce Square |
| Address2 | 2,005 Market Street 39th Floor |
| All Time High | 764.6 |
| All Time Low | 3.29 |
| Ask | 5.61 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 18,320 |
| Average Daily Volume3 Month | 67,943 |
| Average Volume | 67,943 |
| Average Volume10Days | 18,320 |
| Beta | 1.429 |
| Bid | 3.29 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 1.385 |
| City | Philadelphia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.52 |
| Current Ratio | 1.215 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.6 |
| Day Low | 4.32 |
| Display Name | Passage Bio |
| Earnings Timestamp End | 1,772,571,600 |
| Earnings Timestamp Start | 1,772,571,600 |
| Ebitda | -37,579,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.256 |
| Enterprise Value | -9,610,499 |
| Eps Current Year | -11.34 |
| Eps Forward | -10.39 |
| Eps Trailing Twelve Months | -11.96 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7385 |
| Fifty Day Average Change | -0.21850014 |
| Fifty Day Average Change Percent | -0.046111666 |
| Fifty Two Week Change Percent | -39.09986 |
| Fifty Two Week High | 20.0 |
| Fifty Two Week High Change | -15.48 |
| Fifty Two Week High Change Percent | -0.774 |
| Fifty Two Week Low | 3.29 |
| Fifty Two Week Low Change | 1.23 |
| Fifty Two Week Low Change Percent | 0.37386018 |
| Fifty Two Week Range | 3.29 - 20.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,582,900,200,000 |
| Float Shares | 3,201,817 |
| Forward Eps | -10.39 |
| Forward P E | -0.43503368 |
| Free Cashflow | -14,814,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 24 |
| Fullday Change | 0.19 |
| Fullday Change Percent | 4.38799 |
| Fullday Price | 4.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07711 |
| Held Percent Institutions | 1.36101 |
| Implied Shares Outstanding | 3,217,810 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,752,451,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania. |
| Long Name | Passage Bio, Inc. |
| Market | us_market |
| Market Cap | 14,544,501 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_602462727 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -36,112,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,868,761 |
| Number Of Analyst Opinions | 2 |
| Open | 4.32 |
| Operating Cashflow | -33,500,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 267 866 0311 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.52 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 4.33 |
| Price Eps Current Year | -0.39858904 |
| Price Hint | 4 |
| Price To Book | 3.263538 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.166 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.19 |
| Regular Market Change Percent | 4.38799 |
| Regular Market Day High | 4.6 |
| Regular Market Day Low | 4.32 |
| Regular Market Day Range | 4.32 - 4.6 |
| Regular Market Open | 4.32 |
| Regular Market Previous Close | 4.33 |
| Regular Market Price | 4.52 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 21,890 |
| Return On Assets | -0.45619 |
| Return On Equity | -1.69087 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 3,217,810 |
| Shares Percent Shares Out | 0.042600002 |
| Shares Short | 136,935 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 124,628 |
| Short Name | Passage Bio, Inc. |
| Short Percent Of Float | 0.0531 |
| Short Ratio | 5.14 |
| Source Interval | 15 |
| State | PA |
| Symbol | PASG |
| Target High Price | 23.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 15.5 |
| Target Median Price | 15.5 |
| Total Cash | 24,155,000 |
| Total Cash Per Share | 7.507 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -11.96 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.715555 |
| Two Hundred Day Average Change | -3.1955552 |
| Two Hundred Day Average Change Percent | -0.41417047 |
| Type Disp | Equity |
| Volume | 21,890 |
| Website | https://www.passagebio.com |
| Zip | 19,103 |